Literature DB >> 27662300

An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.

Yamila Rodríguez Cruz1,2, Manon Strehaiano3,4,5, Teresita Rodríguez Obaya2, Julío César García Rodríguez1, Tangui Maurice3,4,5.   

Abstract

Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain, particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We previously reported the neuroprotective effect of a low sialic form of EPO, Neuro-EPO, applied intranasally in rodent models of stroke or cerebellar ataxia and in a non-transgenic mouse model of Alzheimer's disease (AD). Here we analyzed the protective effect of Neuro-EPO in APPSwe mice, a reference transgenic mouse model of AD. Mice were administered 3 times a day, 3 days in the week with Neuro-EPO (125, 250 μg/kg) intranasally, between 12 and 14 months of age. Motor responses, general activity, and memory responses were analyzed during and after treatment. The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APPSwe mice were alleviated by the low dose of Neuro-EPO. Oxidative stress, neuroinflammation, trophic factor levels, and a synaptic marker were analyzed in the hippocampus or cortex of the animals. The increases in lipid peroxidation or in GFAP and Iba-1 contents in APPSwe mice were significantly reduced after Neuro-EPO. Activation of intrinsic and extrinsic apoptotic pathways was analyzed. The increases in Bax/Bcl-2 ratio, TNFα, or Fas ligand levels observed in APPSwe mice were reduced by Neuro-EPO. Finally, immunohistochemical and ELISA analyses of Aβ1-42 levels in the APPSwe mouse cortex and hippocampus showed a marked reduction in Aβ deposits and in soluble and insoluble Aβ1-42 forms. This study therefore confirmed the neuroprotective activity of EPO, particularly for an intranasally deliverable formulation, devoid of erythropoietic side effects, in a transgenic mouse model of AD. Neuro-EPO alleviated memory alterations, oxidative stress, neuroinflammation, apoptosis induction, and amyloid load in 14-month-old APPSwe mice.

Entities:  

Keywords:  Alzheimer’s disease; Neuro-EPO; erythropoietin; intranasal formulation; learning and memory; neuroprotection

Mesh:

Substances:

Year:  2017        PMID: 27662300     DOI: 10.3233/JAD-160500

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  19 in total

Review 1.  The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors:  Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal:  Neuromolecular Med       Date:  2019-01-17       Impact factor: 3.843

2.  Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.

Authors:  Rudy Chang; Abrar Al Maghribi; Victoria Vanderpoel; Vitaly Vasilevko; David H Cribbs; Ruben Boado; William M Pardridge; Rachita K Sumbria
Journal:  Mol Pharm       Date:  2018-10-09       Impact factor: 4.939

3.  Intranasal Delivery of Collagen-Loaded Neprilysin Clears Beta-Amyloid Plaques in a Transgenic Alzheimer Mouse Model.

Authors:  Christian Humpel
Journal:  Front Aging Neurosci       Date:  2021-04-22       Impact factor: 5.750

4.  Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke.

Authors:  Garzón Fernando; Rodríguez Yamila; García Julio Cesar; Rama Ramón
Journal:  Behav Sci (Basel)       Date:  2018-02-13

5.  Neuroprotective effects of EpoL against oxidative stress induced by soluble oligomers of Aβ peptide.

Authors:  C Castillo; C Fernández-Mendívil; I Buendia; P Saavedra; C Meza; N C Parra; M G Lopez; J R Toledo; J Fuentealba
Journal:  Redox Biol       Date:  2019-04-02       Impact factor: 11.799

6.  Intranasal erythropoietin ameliorates neurological function impairments and neural pathology in mice with chronic alcoholism by regulating autophagy‑related Nrf2 degradation.

Authors:  Xuedan Nie; Wenbo Wang; Qin Wang; Dan Zhu; Hongshan Song
Journal:  Mol Med Rep       Date:  2018-11-29       Impact factor: 2.952

7.  Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases.

Authors:  Federica Rey; Alice Balsari; Toniella Giallongo; Sara Ottolenghi; Anna M Di Giulio; Michele Samaja; Stephana Carelli
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

8.  Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study.

Authors:  Peir-Haur Hung; Chih-Ching Yeh; Fung-Chang Sung; Chih-Yen Hsiao; Chih-Hsin Muo; Kuan-Yu Hung; Kuen-Jer Tsai
Journal:  Aging (Albany NY)       Date:  2019-09-05       Impact factor: 5.682

9.  Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.

Authors:  Orestes Santos-Morales; Alina Díaz-Machado; Daise Jiménez-Rodríguez; Yaisel Pomares-Iturralde; Tatiana Festary-Casanovas; Carlos A González-Delgado; Sonia Pérez-Rodríguez; Eulalia Alfonso-Muñoz; Carmen Viada-González; Patricia Piedra-Sierra; Idrian García-García; Daniel Amaro-González; Julio César García-Rodríguez; Iliana Sosa-Testé; Alicia Lagarto-Parra; Laura Barrero-Viera; Marlene David-Baldo; Maura Tamayo-Rodríguez; Ivonne Rivero-Vázquez; Gricel González-Gamiz; Alis Martín-Trujillo; Yasmila Rodríguez-Fernández; Ana Alfa Ledo-de la Luz; Maylén Álvarez-Delgado; Ivón Howland-Álvarez; Yolanda Cruz-Gómez
Journal:  BMC Neurol       Date:  2017-07-04       Impact factor: 2.474

10.  In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.

Authors:  Gaëlle Naert; Valentine Ferré; Emeline Keller; Amy Slender; Dorota Gibbins; Elizabeth Mc Fisher; Victor Lj Tybulewicz; Tangui Maurice
Journal:  J Psychopharmacol       Date:  2017-12-07       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.